



ORIGINAL ARTICLE

Synthesis and Study of the Effect New Pyrazoles and Oxadiazole Linked to the 1,4-Dihydropyridine Ring on Breast Cancer

Adiba Saaduldeen Ali, Tahseen Saddam Fandi Al-Mathkuri*

Department of Chemistry, College of Science, University of Misan, Misan, 62001, Iraq

(Received: 11 September 2023)

Accepted: 30 October 2023)

KEYWORDS

Hantzsch reaction;
Hydrazine;
Derivatives;
MTT;
Anti breast cancer

ABSTRACT: The Hantzsch reaction created a new series comprising 1,4-dihydropyridine pyrazoles and oxa diazoles (DHP) by initially synthesizing DHP esters, then its carbohydrates, and subsequent treatment with hydrazine. Pyrazole derivatives (Am_1 and Am_2) were obtained via the reaction of hydrazines with acetylacetone or ethyl acetoacetate, whereas the oxadiazole derivative (Am_3) was prepared via reaction with carbon disulfide in an alkaline medium. The prepared compounds were identified using spectroscopic techniques (FTIR, 1H and ^{13}C NMR, and mass spectrometry). The anti-breast cancer activity of new compounds was evaluated. This cytotoxicity activity afforded that compound (AS) was the strongest in this group together with an $IC_{50} = 100.24 \mu g mL^{-1}$, whereas compound (AT) demonstrated the lowest potency, with an IC_{50} value of $300 \mu g mL^{-1}$. The Hantzsch reaction was used in the synthesis of a new 1,4-dihydropyridine that has pyrazole and oxadiazole moieties. The activity of *in vitro* cytotoxicity (MTT cell viability assay) was determined. *In vitro* MCF7 cells were used in the evaluation of the cytotoxicity activity (MTT cell viability assay) of new compounds. This cytotoxicity activity meant that compound (AS) was the strongest in this group, with an IC_{50} of $100.24 \mu g mL^{-1}$, while compound (AT) had the least potency, with an IC_{50} value of $300 \mu g mL^{-1}$. Based on our findings, we can infer that 1,4-dihydropyridine derivatives (DHPs) are noteworthy heterocyclic compounds with pharmacological potential. This cytotoxicity activity meant that compound (AS) was the strongest in this group, with an IC_{50} of $100.24 \mu g mL^{-1}$, while compound (AT) had the least potency, with an IC_{50} value of $300 \mu g mL^{-1}$.

INTRODUCTION

1,4-dihydropyridine was discovered as a derivative of an important class of heterocyclic compounds, and it is a useful commercial molecule as a calcium channel blockers due to its wide range of pharmacological and biological activities. There are more than 12 commercially valid and clinically important drugs on the market that include nucleophilic 1,4-DHP, such as Nifedipine, Felodipine, and Nicardipine as shown in Figure 1 which are used to treat cardiovascular diseases. 1,4-dihydropyridine (DHP) is a class of organic compounds that contain a pyridine ring with two

hydrogen atoms added to the 1 and 4 positions. The general chemical formula for DHP is C_5H_7N . DHP compounds have various applications in chemistry, medicine, and industry [1].

One of the well-known applications of 1,4-dihydropyridine derivatives is in the field of medicine, particularly in cardiovascular pharmacology [2]. Several DHP derivatives are widely employed as calcium channel [3] blockers (CCBs) [4], including nifedipine, nimodipine, and amlodipine. These medications cause blood arteries to widen and relax by blocking calcium

ion entry into smooth muscle cells. So, they are prescribed for illnesses including hypertension (high blood pressure), angina (chest discomfort), and certain arrhythmias (irregular cardiac rhythms) [5].

The potential of 1,4-dihydropyridines has been investigated for uses outside of the cardiovascular

system. Antioxidant capabilities and neuroprotective effects of several DHP derivatives in situations like Parkinson's disease and Alzheimer's have been studied. The possibility of DHP compounds acting as catalysts in organic synthesis reactions has also been investigated [6, 7].




Figure 1. the most well-known 1,4-DHP calcium channel blockers' structures.

The nitrogen atoms in pyrazole are located next to one another in the ring's five-membered structure. $C_3H_2N_2$ is its chemical formula. The pharmaceutical sector frequently employs the utilization of pyrazole, as it is seen as a simple and flexible building block in chemical synthesis. It has several different biological effects, such as reducing inflammation and pain, as well as lowering body temperature [8].

Naproxen and ibuprofen, two examples of NSAIDs, were both synthesized using pyrazole derivatives. Cancer, neurological problems, and infectious diseases have all been studied in relation to pyrazole-based drugs. There are two nitrogen atoms and one oxygen atom in the ring of oxadiazole, making it a heterocyclic molecule with five members. C_2HN_2O is its chemical formula. Due to their wide range of biological activities and medicinal chemistry applications [9-13], oxadiazole derivatives have garnered a lot of interest. Oxadiazoles have been the subject of intense research due to their potential to kill bacteria, fungi, and cancer cells. They've also shown promise as anti-inflammatories, painkillers, and anti-convulsants. For optoelectronic applications, oxadiazole derivatives have also been studied as organic semiconductors and luminous materials [14,15]. Because of their useful pharmacological characteristics and synthetic flexibility, pyrazole and oxadiazole derivatives have played important roles in the drug discovery and development processes[16-24]. The purpose of this study is to create novel DHP derivatives with an oxadiazole or pyrazole group and test their efficacy against breast cancer. All novel derivatives were characterized via IR,

1H NMR, and ^{13}C NMR spectroscopy in addition to mass analysis.

MATERIALS AND METHODS

Chemistry

A digital Stuart SMP-11 device was used to determine the melting point in an open capillary tube. The Perkin-Elmer 293 FTIR spectrophotometer was used to measure the infrared spectra using KBr disks. Using TMS as the internal standard and DMSO-d₆ as the solvent, the 1H and ^{13}C NMR spectra were calculated using a Bruker DRX 400 spectrometer.

Synthesis of 9-(4-hydroxyphenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione(AT)

(0.122g (0.001 moles) of *p*-hydroxybenzaldehyde and 0.28 g (0.002 moles) of dimedon with 0.308 g (0.004 moles) of ammonium acetate and iodine (15 mol%) in 40 mL of ethanol The reaction mixture was heated under reflux for 4 hours. The reaction was monitored by thin-layer chromatography (TLC). The reaction was cooled, filtered, and recrystallized from methanol to give a yellow solid [25]. Yiled 76% M.P.(300-302 . YieldedR (KBr,IR(KBr,cm⁻¹), 3275, 3197, 2954, 1612, 1508, 1222, 114 ¹H-NMR(DMSO-d₆δ(ppm)9.22(S,1H,NH),9.02(S,1H,OH OH), 6.9(d, 2H,J=8Hz CH),6.5(d, 2H,J=8Hz CH),4.69(S,1H,CH),2.45(d,2H,CH₂),2.18(d, 2H,CH₂), 2.18 (d,2H,CH₂)1.00-0.86 (s,12H,CH₃),¹³C-NMR(DMSO-d₆δ(pp m)193.77, 154 .40,148.27,

137.30127.81, 113. 66,111.23,50.6, 40.59, 31. 32, 31.06, 28.52, 25.83, MS(70 Ev), C₂₃H₂₇NO₃, m/z: (M⁺),Calcd for 365.20 found 366.3.

Synthesis of ethyl 2-4-3,3,6,6-tetramethyl 1,8-dioxo-1,2,3, 4,5,6,7, 8,9,10 -decahydroacridin-9-ylphenoxyacetate(AS)

Equimolars amount of compound 1 (0.365G, 0.001 mmol) and chloroethyl acetate (0.16 ml, 0.0015 mmol) were mixed, and then K₂CO₃ (0.276 g, 0.002 mmol) was added in 10 ml of DMSO. The mixture was cooled to room temperature and subsequently poured into ice water.. The product was filtered, dried, and further purified by column chromatography. (DCM: MeOH) (4:6 v/v). Pale yellow crystal. Yield (68%), m.p.174-171°C [26], IR (KBr,cm⁻¹), 3209, 3066, 2958, 1755, 1627, 1483. ¹H-NMR (DMSO-d₆\ppm), 9.28 (s, 1H, NH), 7.05 (d, 2H, J = 6.75Hz, CH), 6.7 (d, 2H, J=8 Hz, CH), 4.75 (s, 1H, CH), 4.66 (s, 2H, OCH₂CO),4.16 (m,2H, OEt),2.45 (d,2H, CH₂),2.18(d,2H, CH₂),1.20 (t, 3H, J=8Hz, CH₃), 1.00-0.86 (s, 12H, CH₃) ¹³C-NMR(DMSO-d₆\ppm) 194.86, 169.36, 155.91, 140.68, 113.99, 128.9, 149.59, 112.06, 65.02, 61.01,50.71, 40.59, 32.62, 32.38, 29.54, 27.03 14.49, MS(70 Ev), C₂₇H₃₃NO₅, m/z:(M⁺),Calcd for 451.5 found 451.4.

Synthesis of 2,4,3,3,6,6-tetramethyl-1,8-dioxo-1,2,3,4, 5,6,7,8 ,9 ,10-decahydroacridin-9-yl-phenoxyacetohydrazid(Am)

A mixture of (0.437 g, 0.001 mole) (2) and (0.14 ml, 0.003 mole) hydrazine hydrate was refluxed in 40 ml of ethanol for 3 hours. After cooling, the reaction mixture was poured over crushed ice. the solid product Filtering was done, as was recrystallization from ethanol.Yellow crystal, Yield 62%, m.p.215-213°C[27], IR(KBr,cm⁻¹),3305,3167 ,3047, 2958 , 1697,1620,1504,1219,1076, ¹H-NMR(DMSO-d₆\ppm) ,9.27 (S,1H,NH), 9.25 (S,1H ,CONH),7.05 (d,2H,J=8.2Hz,CH) ,6.74(d, 2H,J=8Hz, CH), 4.75 (S,1H,CH) ,4.38 (S, 2H ,OCH₂CO),4.31(S,2H,NH₂),2.45(d,2H,CH₂), 2.18(d,2H, CH₂), 1.00-0.86(S, 12H, CH₃). ¹³C-NMR(DMSO-d₆\ppm) ,194.86, 167.29,156.13, 140.62, 128.95, 114.14, 149.57, 112.09, 66.64, 50.73,40.60, 32.62,32.43, 29.54, 27.04.

synthesis of DHP-Pyrazole (Am₁,Am₂) [28]

A mixture of DHP carbohydrazide (3) (0.437.0.001 mol) with acetylacetone or ethyl acetoacetate (0.0012 mol) in MeOH (10 mL) was heated under reflux for 3 hours. The reaction mixture was cooled, filtered, and the chromatography column purified using dichloromethane/methanol.

9,4,2,3,5-dimethyl-1H-pyrazol-1-yl-2-oxoethoxyphenyl-3,3,6,6-tetramethyl -3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione(Am₁)

Yellow crystal, Yield 81%, m.p.204-200°C, IR (KBr,cm⁻¹),3194, 3074, 2958, 1639,1697,1558, 1504,1222,1076,¹H-NMR(DMSO-d₆,δ ppm), 9.26(S,1H, NH), 7.03(d,2H, J=8.2Hz, CH),6.8(d,2H, J=8.2Hz, CH), 6.4(S,1H, CH),4.79(S,2H, OCH₂CO) 4.75(S,1H, CH), 2.45(d,2H, CH₂), 2.18(d,2H, CH₂),1.97(S,3H, CH₃), 1.74 (S,3H, CH₃), 1.00-0.86(S,12H, CH₃), ¹³C-NMR(DMSO-d₆\ppm), 194.90, 165.48 ,156.56, 155.94 ,149.57,140.20,128.87,113.98,112.13,90.8 66.11, 50.73, 40.62, 32.64, 32.35,29.53 ,27.08,26.30,16.37. MS(70 Ev), C₃₀H₃₅N₃O₄, m/z:(M⁺),Calcd for 501.26 found 501.4

3,3,6,6-tetramethyl-9,4,2,3-methyl-5-oxo-4,5-dihydro-1Hpyrazol-1-yl-2-methoxyphenyl-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dion (Am₂),

Orange crystals, Yield 30% m.p.150-147°C. , IR(KBr,cm⁻¹),3197,3066, 2954, 1643, 1697, 1620,1558,1485,1222,1080, ¹H-NMR (DMSO-d₆\ppm) 9.26 (S,1H,NH) ,7.05 (d,2H,J=8Hz),6.71 (d,2H,J=8Hz,CH), 4.6(S,2H,OCH₂CO) 4.75 (S,1H,CH), 3.67 (S,3H ,CH₃) 2.45 (,2H,CH₂), 2.18(d,2H,CH₂) ,1.97 (d,2H,CH₂),1.75 (S,3H,C H₃)1.00-0.86 (S,12H,CH₃) ¹³C-NMR(DMSO-d₆\ppm), 194.86 ,169.86,155.9 149.60, 140.70 ,128.99 ,113.99,112.05,64.93,52.21,50.72,32.62,32.37,29.51, 27.07.MS(70 Ev), C₂₉ H₃₃ N₃O₅, m/z:(M⁺),Calcd for 503.6 found509.

Synthesis of 3,3,6,6-tetramethyl-9,4,5-methyl-1,3,4 oxadiazol-2-yl-methoxy phenyl -3,4,6,7,9,10 -hexahydroacridine -1,8,2H, 5H-dione(Am₃)

Potassium hydroxide (0.056 g, 0.05 mol) was added to hydrazide solution (0.437 g, 0.001 mol) in methanol (10 mL). (0.1 mL, 0.002 mol) of carbon disulfide was added dropwise to the reaction mixture. The reaction mixture was refluxed for 8 hours, and the product was collected by filtration and then dissolved in water. The solution is acidified by adding 10% HCl with stirring, and the solid product is filtered and recrystallized from methanol [29]. Yellow crystal, the yield of 56%.M.P. 233-230°C, IR(KBr,cm⁻¹), 3286, 3059, 2958, 1639, ¹H-NMR (DMSO-d₆\ppm), 9.27(S,1H,NH), 7.09 (d, 2H, J=8Hz, CH), 6.8 (d,2H,J =8.2Hz,CH),5.12(S,2H,CH₂), 4.76 (S, 1H, CH), 2.45(d, 2H, CH₂), 2.18 (d, 2H, CH₂), 1.00-0.86(s,12H,CH₃),¹³C-NMR (DMSO-d₆, δ ppm), 194.86, 178.7 160.13, 155.57, 149.66, 141.29, 129.11, 114.31, 111.97, 50.70, 40.60, 32.63, 32.44, 29.52, 27.05. MS(70 Ev), C₂₆H₂₉N₃O₄S, m/z:(M⁺),Calcd for 479.6 found 479.5.

RESULTS AND DISCUSSION

The synthesis of 1,4-dihydropyridine derivatives as illustrated in Figure 2 from the Hantzsch method by 4-hydroxybenzaldehyde was refluxed with two equivalents of dimedone and NH⁺OAC in the presence of iodine in an ethanol medium. The product (AS) was created by alkylating the OH group with ethylchloroacetate in DMSO. Only the phenolic OH group of the DHP ring is alkylated under such mild circumstances; the NH group is not. By refluxing the resultant ester (AS) with hydrazine hydrate in ethanol for roughly 4 hours, it was changed into its hydrazide (Am) through a nucleophilic substitution reaction. It's interesting to note that under these circumstances, the stable ester groups on the DHP ring were unaffected [30]. By condensing hydrazide (Am) with different ethyl aceto acetate or acetylacetone and ketones in a medium of methanol, Figure 3 [28] target pyrazole was produced. By reacting hydrazide (Am) with carbon disulfide in methanolic potassium hydroxide, 1,3,4-oxdiazole was produced [31]. All the synthesized compounds were identified by IR, ¹H-NMR, ¹³C-NMR, DEPT-135, and mass spectra. The IR data of compound AT as shown in Figure 4 showed strong bandings at 3150–3500 cm⁻¹ and 17150 cm⁻¹ due to vibrational expansion of the NH/OH and ketone carbonyl groups, respectively, and this was further confirmed by the ¹H-

NMR spectrum in Figure 5, which displays a single signal at 9.22 and 9.02 ppm, which are attributed to the phenolic OH and NH proton of the DHP ring, respectively. As for the ¹³C-NMR spectrum, it was shown by a signal at 193.77 ppm belonging to the carbonyl ketone group, and other signals at 50.6) ppm belonging to the CH₂ group and the DHP ring, as shown in Figure 6. The mass spectrum of (AT) is shown in Figure 7.

In addition, as can be deduced from Table 1, it reveals that the observed [M⁺] is in good agreement with the calculated [M+]. The ¹H-NMR spectrum Figure 8 of AS showed two new signals, the first double due to the resonance of the OCH₂ proton and the second triple due to the resonance of the CH₃ protons of the OCH₂CH₃ ester group at the stop groups δ1.20 ppm and 4.15 ppm, respectively. 4.69 ppm belonged to the proton resonance of OCH₂CO, proving that the phenolic hydroxyl group suffered an addition reaction and not the NH amine group in the DHP ring. The ¹³C-HNMR spectrum is shown in Figure 9. a signal at (169.36) returning to the esterification carbonyl group while preserving the carbonyl structure of the DHP ring, and this was confirmed by DEPT-135 as shown in Figure 10. The mass spectrum of the compound AS is shown in Figure 11. as can be deduced from Table 1, it reveals that the observed [M⁺] is in good agreement with the calculated [M⁺]. In FTIR, hydrazide (Am) in Figure 12 spectrum, shifting the carbonyl expansion The frequency of 1759 cm⁻¹ to a reduced frequency of 1697 cm⁻¹ indicates formation of Am. Moreover, its ¹H-NMR spectrum displayed two segments at 9.25 and 4.31 ppm confirming the presence of NH and NH₂ hydrazides as shown in Figure 13. The ¹³C-NMR spectrum showed a signal at 167.29 ppm belonging to the amide carbonyl group, with the capone structure remaining, and this was confirmed by the DEPT-135 spectrum, as shown in the Figure 14, and Figure 15. The FTIR spectra (Am₁) and (Am₂) revealed the elimination of three absorption bands caused by NH₂ and NH groups as well as the emergence of a stretching band at 1558 cm⁻¹ caused by a C=N band and a new absorption band at 1643 cm⁻¹ caused by a C=O (endocyclic) group as shown in Figure 16, and Figure 17. The ¹H-NMR spectrum of Figure 18 of compound Am₁ showed new signals at a chemical displacement of 6.49

ppm due to C - H proton resonance in the pyrazole ring, The ¹H-NMR spectrum of compound in Figure 19 while the protons of CH₂-(pyrazole) appeared as a singlet at δ2.45 ppm and another singlet signal appeared at δ3.67 ppm due to three protons of CH₃ group. For compound

(Am₃) the infrared spectrum of Figure 20 showed that 2748cm⁻¹ belongs to the SH group of the new oxadiazole ring, and the ¹H-NMR spectrum in Figure 21 showed a signal at 14.6 ppm as a result of the SH proton resonance.

Table 1. Mass Spectra data for 1,4-Dihydropyridine (DHP) Pyrazoles and oxadiazole derivatives.

Compound	Structure	Calculate M ⁺	Found M ⁺
AT	C ₂₃ H ₂₇ NO ₃	365.20	366.3
AS	C ₂₇ H ₃₃ NO ₅	451.5	451.4
Am ₁	C ₃₀ H ₃₅ N ₃ O ₄	501.26	501.4
Am ₂	C ₂₉ H ₃₃ N ₃ O ₅	503.6	509
Am ₃	C ₂₆ H ₂₉ N ₃ O ₄ S	479.6	479.5




Figure 2. Synthesis pathway of DHPs hydrazide.






Figure 3. Preparation pathway of DHPs derivatives.






Figure 6. ¹³C NMR spectrum of compound AT.




Figure 7. Mass spectrum of compound AT




Figure 8. ¹H NMR spectra of compound AS




Figure 9. ¹³C NMR spectrum of compound AS.




Figure 10. DEPT-135 spectrum of compound AS.

File :C:\MSDCHEM\1\DATA\Snapshot\AS-OZ.D
 Operator :
 Acquired : 1 Jul 2023 20:36 using AcqMethod default.m
 Instrument : directmass
 Sample Name:
 Misc Info :
 Vial Number: 1




Figure 11. Mass spectrum of compound AS.

4/19/2023 9:12:31 AM

BPC-Analysis Center




Figure 12. IR spectra of compounds Am.




Figure 13. ¹H NMR spectra of compound Am.




Figure 14. ¹³C-NMR spectrum of compound Am.




Figure 15. DEPT-135 spectrum of compound Am.

4/19/2023 10:28:28 AM

BPC-Analysis Center




Figure 16. IR spectra of compounds Am₁.

4/19/2023 10:22:15 AM

BPC-Analysis Center




Figure 17. IR spectra of compounds Am₂.

Activate Windows
Go to Settings to activate




Figure 18. ¹H NMR spectra of compound Am₁.




Figure 19. ¹H- NMR spectra of compound Am₂




Figure 20. IR spectra of compounds Am₃.




Figure 21. ¹H- NMR spectra of compound Am₃

Biological activity

Synthesized substances' cytotoxic effects on a strain of human breast cancer cells(MCF-7)

The term "IC₅₀" refers to a notion that is frequently employed in the pharmaceutical industry as a measure of the effectiveness of an agent's ability to inhibit a particular biological or biochemical process. Its value reveals the anti-inhibitory level needed to a halving a given biology or biochemistry activity. Higher IC₅₀ values compared to compounds with lower IC₅₀ values,

indicates weaker inhibitory activity of the substance. The MCF-7 cell line was used in this investigation to test the antiproliferative activity of the compounds (AT-AS-Am₁-Am₂-Am₃). As shown in Figure 22, compound (AS) within this group, was the most effective with an IC₅₀ value of 100.24µg mL⁻¹, and (AT) was the least potent with an IC₅₀ value of 300µg mL⁻¹, as displayed in Figure

23. To validate the IC_{50} calculation, a microscopic analysis of the tested compounds in the cell line at a concentration of $300 \mu\text{g mL}^{-1}$ was conducted, The pharmacological profile of the heterocyclic moiety

pyrazole is notable, The pyrazole template is one-of-a-kind and has been linked to a wide range of biological processes [32-34].



Figure 22. MCF-7 cell line under microscopic examination of control and compounds at $300 \mu\text{m}$ concentration.




Figure 23. The IC₅₀ Values of compounds against MCF-7 Cell line.

CONCLUSIONS

Hansch's condensation process was used to synthesize a new series of 1,4-dihydropyridine derivatives containing 1,3,4-oxadiazole and pyrazole moieties. These compounds were elucidated using spectroscopic techniques such as infrared, ¹H, and ¹³C-NMR, as well as mass analysis. This technique is simple and easy to use to synthesize pyrazole and oxadiazole. The researchers looked at the effectiveness of these substances in the fight against breast cancer.

ACKNOWLEDGEMENTS

We would thank the Department of Chemistry staff For their help us and support in completing this Study.

Conflicts of interest

The authors declare there are no conflicts of interest.

REFERENCES

1. Nasr-Esfahani M., Rafiee Z., Kashi H., 2016. Nanoparticles tungstophosphoric acid supported on polyamic acid: catalytic synthesis of 1, 8-dioxodecahydroacridines and bulky bis (1, 8-dioxodecahydroacridine) s. Journal of the Iranian Chemical Society. 13,1449-1461.
2. Khodja I.A., Ghalem W., Dehimat Z.I., Boulcina R., Carboni B., Debache A., 2014. Solvent-Free Synthesis of Dihydropyridines and Acridinediones via a Salicylic Acid-Catalyzed Hantzsch Multicomponent Reaction. Synthetic Communications. 44(7), 959-967.
3. Ibrahim N.S., Mohamed M.F., Elwahy A.H., Abdelhamid I.A., 2018. Biological activities and docking studies on novel Bis 1, 4-DHPS linked to arene core via ether or ester linkage. Letters in Drug Design & Discovery. 15(10), 1036-1045.
4. Olejníková P., ŠVORC L., Olšovská D., Panáková A., Vihonská Z., Kovaryová K., Marchalín Š., 2014. Antimicrobial activity of novel C2-substituted 1, 4-dihydropyridine analogues. Scientia pharmaceutica. 82(2), 221-232.
5. Vijesh A.M., Isloor A.M., Peethambar S.K., Shivananda K.N., Arulmoli T., Isloor N.A., 2011. Hantzsch reaction: synthesis and characterization of some new 1, 4-dihydropyridine derivatives as potent antimicrobial and antioxidant agents. European Journal of Medicinal Chemistry. 46(11), 5591-5597.
6. Fan X., Li Y., Zhang X., Qu G., Wang J., 2007. An efficient and green preparation of 9- arylacridine- 1, 8-dione derivatives. Heteroatom Chemistry: An International Journal of Main Group Elements. 18(7),786-790.
7. Bade T.S., Ebrahimi H.P., Alsalm T.A., Titinchi S.J., Abbo H.S., Bolandnazar Z., Ebrahimi A., 2017. A novel series of 1, 4-Dihydropyridine (DHP) derivatives bearing thiazolidin-4-one: From synthesis to structure. Journal of Molecular Structure. 1138,136-148.
8. Al-Wahaibi L.H., Mohamed A.A., Tawfik S.S., Hassan H.M. and El-Emam A.A., 2021. 1, 3, 4-Oxadiazole N-Mannich bases: synthesis, antimicrobial, and anti-proliferative activities. Molecules. 26(8), 2110.
9. Kumar B.P., Rao A.T., Prasad V.S.R., Shree A.J., 2016. Synthesis of novel 1, 3, 4-oxadiazole analogues with expected antibacterial activity. International Journal of Chemical Sciences. 14, 1877-1885.
10. Sharma M., Singhvi I., Ali Z.M., Kumar M., Dev S.K., 2018. Synthesis and biological evaluation of natural cyclic peptide. Future Journal of Pharmaceutical Sciences. 4(2), 220-228.
11. Chandrakantha B., Shetty P., Nambiyar V., Isloor N., Isloor A.M., 2010. Synthesis, characterization and biological activity of some new 1, 3, 4-oxadiazole bearing 2-flouro-4-methoxy phenyl moiety. European Journal of Medicinal Chemistry. 45(3), 1206-1210.
12. Sattar A., Abbasi M.A., Siddiqi S.Z., Nafeesa K., Ahmad I., 2016. Synthesis and antibacterial study of some s-substituted aliphatic analogues of 2-mercapto-5-(1-(4-toluenesulfonyl) piperidin-4-yl)-1, 3, 4-oxadiazole. Tropical Journal of Pharmaceutical Research. 15(6), 1267-1274.
13. Küçükgüzel Ş.G., Oruç E.E., Rollas S., Şahin F., Özbek A., 2002. Synthesis, characterisation and biological activity of novel 4-thiazolidinones, 1, 3, 4-oxadiazoles and some related compounds. European Journal of Medicinal Chemistry. 37(3),197-206.
14. Maslat A.O., Abussaud M., Tashtoush H., Al-Talib M., 2002. Synthesis, antibacterial, antifungal and

- genotoxic activity of bis-1, 3, 4-oxadiazole derivatives. Polish Journal of Pharmacology. 54(1),55-60.
15. Khalilullah H., J Ahsan M., Hedaitullah M., Khan S., Ahmed B., 2012. 1, 3, 4-oxadiazole: a biologically active scaffold. Mini Reviews in Medicinal Chemistry. 12(8), 789-801.
16. Poudyal B., Bharghav G., 2021. A review of pyrazole an its derivative. National Journal of Pharmaceutical Sciences. 1(1), 34-41.
17. Azzam R.A., Elsayed R.E., Elgemeie G.H., 2020. Design, synthesis, and antimicrobial evaluation of a new series of N-sulfonamide 2-pyridones as dual inhibitors of DHPS and DHFR enzymes. ACS omega. 5(18), 10401-10414.
18. Çetin G., Cetin B., Colak B., Asan M., Demirel G., Cansaran Duman D.E.M.E.T., Akcelik N., Şimsek R., 2022. A new perspective for biological activities of novel hexahydroquinoline derivatives. Journal of Research in Pharmacy. 26(1), 219-230.
19. Murthy Y.L.N., Rajack A., Ramji M.T., Praveen C., Lakshmi K.A., 2012. Design, solvent free synthesis, and antimicrobial evaluation of 1, 4 dihydropyridines. Bioorganic & Medicinal Chemistry Letters. 22(18), 6016-6023.
20. Sanchez L.M., Sathicq Á.G., Jios J.L., Baronetti G.T., Thomas H.J., Romanelli G.P., 2011. Solvent-free synthesis of functionalized pyridine derivatives using Wells-Dawson heteropolyacid as catalyst. Tetrahedron Letters. 52(34), 4412-4416.
21. Zhang Y., Wu C., Zhang N., Fan R., Ye Y., Xu J., 2023. Recent Advances in the Development of Pyrazole Derivatives as Anticancer Agents. International Journal of Molecular Sciences. 24(16), 12724.
22. Kagne R.P., Nikam G.H., Kalalawe V.G., Niwadange S.N., Munde D.R., 2017. An efficient protocol for synthesis of 1, 4-dihydropyridine derivatives by using graphene oxide nano particles as a catalyst. Journal of Chemistry and Chemical Science. 7, 1064.
23. Bazargan L., Fouladdel S., Shafiee A., Amini M., Ghaffari S.M., Azizi E., 2008. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro. Cell Biology and Toxicology. 24, 165-174.
24. Movassagh B., Rooh H., Bijanzadeh H.R., 2013. A mild and highly efficient one-pot synthesis of 1, 3, 5-triaryl-2-pyrazolines. Chemistry of Heterocyclic Compounds. 48(11),1719-1721.
25. Ko S., Yao C.F., 2006. Ceric ammonium nitrate (CAN) catalyzes the one-pot synthesis of polyhydroquinoline via the Hantzsch reaction. Tetrahedron. 62(31), 7293-7299.
26. Linciano P., Benedetti R., Pinzi L., Russo F., Chianese U., Sorbi C., Altucci L., Rastelli G., Brasili L., Franchini S., 2021. Investigation of the effect of different linker chemotypes on the inhibition of histone deacetylases (HDACs). Bioorganic Chemistry. 106, 104462.
27. Pattao S.R., Rabara P.A., Pattan J.S., Bukitagar A.A., Wakalc V., Musmade D., 2009. Synthesis and evaluation of some novel substituted 1, 3, 4-oxadiazole and pyrazole derivatives for antitubercular activity. Indian Journal of Chemistry. Sect. B: Organic chemistry, including medical chemistry. 48(10), 1453-1456.
28. Tomma J.H., Hussein D.F., Jamel N.M., 2016. Synthesis and Characterization of Some New Quinoline-2-one, Schiff bases, Pyrazole and Pyrazoline Compounds Derived From Hydrazide Containing Isoxazoline or Pyrimidine Cycles. Iraqi Journal of Science. 1316-1332.
29. Mayekar A.N., Yathirajan H.S., Narayana B., Sarojini B.K., Kumari N.S., 2010. Synthesis and antimicrobial studies on new substituted 1, 3, 4-oxadiazole derivatives bearing 6-bromonaphthalene moiety. International Journal of Chemistry. 2(1), 38.
30. Ulloora S., Shabaraya R., Ranganathan R., Adhikari A.V., 2013. Synthesis, anticonvulsant and anti-inflammatory studies of new 1, 4-dihydropyridin-4-yl-phenoxycetohydrazones. European Journal of Medicinal Chemistry. 70, 341-349.
31. Gowda J., Khadar A., Kalluraya B., Kumari N.S., 2010. Microwave assisted synthesis of 1, 3, 4-oxadiazoles carrying benzimidazole moiety and their antimicrobial properties. Indian Journal of Chemistry. Sect. B: Organic chemistry, including medical chemistry. 49(8), 1130-1134.
32. Mulugeta E., Samuel Y., 2022. Synthesis of benzimidazole-sulfonyl derivatives and their biological activities. Biochemistry Research International. <https://doi.org/10.1155/2022/7255299>.
33. Alam M.J., Alam O., Naim M.J., Nawaz F.,

Manaihiya A., Imran M., Thabet H.K., Alshehri S., Ghoneim M.M., Alam P., Shakeel F., 2022. Recent advancement in drug design and discovery of pyrazole biomolecules as cancer and inflammation therapeutics. *Molecules*. 27(24), 8708.

34. Sophy M.A., Abdel Reheim M.A.M., 2020. Synthesis of Some New 1, 3, 4-Oxadiazole, Pyrazole, and Pyrimidine Bearing Thienopyrazole Moieties. *Current Organic Synthesis*. 17(8), 661-670.

